A drug that showed promise in treating a sleep disorder could potentially help slow symptoms, experts say.

Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the completion of enrollment for the REPLACE™ Phase 1b ...

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than 10 million people ...